Correlation Between Mineralys Therapeutics, and Replimune
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Replimune Group, you can compare the effects of market volatilities on Mineralys Therapeutics, and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Replimune.
Diversification Opportunities for Mineralys Therapeutics, and Replimune
0.15 | Correlation Coefficient |
Average diversification
The 3 months correlation between Mineralys and Replimune is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Replimune go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and Replimune
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Replimune. But the stock apears to be less risky and, when comparing its historical volatility, Mineralys Therapeutics, Common is 1.03 times less risky than Replimune. The stock trades about -0.18 of its potential returns per unit of risk. The Replimune Group is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest 1,262 in Replimune Group on November 4, 2024 and sell it today you would earn a total of 136.00 from holding Replimune Group or generate 10.78% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. Replimune Group
Performance |
| Timeline |
| Mineralys Therapeutics, |
| Replimune Group |
Mineralys Therapeutics, and Replimune Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and Replimune
The main advantage of trading using opposite Mineralys Therapeutics, and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.The idea behind Mineralys Therapeutics, Common and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Replimune vs. Nuvalent | Replimune vs. Ventyx Biosciences | Replimune vs. Ascendis Pharma AS | Replimune vs. United Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Complementary Tools
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |